Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 242

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 242
---
, or if greater, at the level in effect immediately prior to the Change of Control, plus (B) his target bonus in effect for the fiscal year in which his termination
of employment occurs, (ii) if he elects COBRA coverage, up to twelve months of reimbursement of a portion of each COBRA premium payment equal to the portion the Company contributed to such health insurance premium cost as of the date of
termination, and (iii) full accelerated vesting of all then-outstanding and unvested equity awards to acquire the Company’s common stock. Payment of any severance payments to Mr. Ball pursuant to the Ball Employment Agreement is
contingent on his execution and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company, and provided that such release becomes effective and irrevocable no later than 60 days following the
termination date.

Retention Agreements

The Company
has entered into Retention Bonus Letters with each of Dr. Lennon and Messrs. Giacobello and Ball, pursuant to which each executive is eligible to be paid a Retention Bonus subject to continued employment with the Company through the earlier of
(i) March 31, 2025, or (ii) the date of a Change in Control (as defined in

- 165 -

the applicable Retention Bonus Letter), provided that an executive will remain eligible to receive the Retention Bonus if his employment is terminated by the Company other than for Cause, death
or disability, or if he resigns for Good Reason (each such term as defined in the applicable Retention Bonus Letter), subject to execution of a separation agreement and release of claims in favor of the Company. The amount of such Retention Bonus is
$390,000 for Dr. Lennon, $220,000 for Mr. Giacobello and $210,000 for Mr. Ball.

Effective Arrangements with Drs. Desai and Itri

Transition Agreement and Release with Neil Desai, Ph.D.

Dr. Desai terminated employment as our Executive Chairman, effective as of October 1, 2024.

Pursuant to the terms of a Transition Agreement and Release entered into between Dr. Desai and the Company, dated October 16, 2024, Dr. Desai
became eligible to receive the following: (i) continuing payments of severance pay in the aggregate amount of $1,072,539, payable over a period of 18 months, (ii) payment